CLS Therapeutics
CLS Therapeutics is a New York City-based biopharmaceutical company focused on developing innovative gene therapies for cancer, particularly targeting circulating cell-free DNA. Their mission is to translate circulating nucleic acid science into transformative treatments for cancers with unmet medical needs, starting with pancreatic cancer. They are working on their first-in-class candidate CLS-014, a gene therapy designed to combat cancer by targeting serum cell-free DNA.
Industries
Nr. of Employees
small (1-50)
CLS Therapeutics
New City, New York, United States, North America
Patents
Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
US-11905522-B2
View DetailsMethod for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
US-8871200-B2
View Details
Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
US-11905522-B2
View DetailsMethod for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
US-8871200-B2
View DetailsProducts
AAV-based gene therapy encoding DNase I for degradation of circulating cfDNA
A preclinical gene therapy candidate using an adeno-associated vector to express recombinant DNase I with the objective of reducing circulating cell-free DNA levels to inhibit tumor growth and metastasis.
CLS-014
First-in-class anticancer gene therapy designed to increase blood DNase I level, destroying circulating cancer cfDNA and inhibiting primary tumor growth and metastasis formation.
AAV-based gene therapy encoding DNase I for degradation of circulating cfDNA
A preclinical gene therapy candidate using an adeno-associated vector to express recombinant DNase I with the objective of reducing circulating cell-free DNA levels to inhibit tumor growth and metastasis.
CLS-014
First-in-class anticancer gene therapy designed to increase blood DNase I level, destroying circulating cancer cfDNA and inhibiting primary tumor growth and metastasis formation.
Expertise Areas
- Gene therapy development
- Circulating cell-free DNA biology
- Oncology drug discovery (pancreatic, liver, stomach cancers)
- Preclinical development and translational research
Key Technologies
- Adeno-associated virus (AAV) vector delivery
- Recombinant enzyme (DNase I) expression
- Gene therapy platforms
- Circulating cell-free DNA targeting
News & Updates
CLS Therapeutics’ project entered the final of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.
CLS Therapeutics’ project has been selected as one of the semi-finalists of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.
CLS Therapeutics announced that it will present at the 2021 American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting.
Xenetic Biosciences announced the signing of a patent assignment from CLS Therapeutics related to collaboration with VolitionRx Limited and CLS, involving the transfer of a patent and issuance of 850,000 shares of common stock to CLS.
George Tetz, MD, Ph.D., CEO of CLS Therapeutics, presented a poster on their transformative anticancer gene therapy platform at the Cancer Metabolism and Signaling conference organized by the New York Academy of Sciences.
George Tetz, MD, Ph.D., CEO of CLS Therapeutics, presented a poster on their anticancer gene therapy platform at the Targeting Tumor Heterogeneity Conference organized by the New York Academy of Sciences.
CLS Therapeutics’ project entered the final of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.
CLS Therapeutics’ project has been selected as one of the semi-finalists of “Creating the World·Sailing to the Future” Innovation and Entrepreneurship Competition 2022 Hangzhou.
CLS Therapeutics announced that it will present at the 2021 American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting.
Xenetic Biosciences announced the signing of a patent assignment from CLS Therapeutics related to collaboration with VolitionRx Limited and CLS, involving the transfer of a patent and issuance of 850,000 shares of common stock to CLS.
George Tetz, MD, Ph.D., CEO of CLS Therapeutics, presented a poster on their transformative anticancer gene therapy platform at the Cancer Metabolism and Signaling conference organized by the New York Academy of Sciences.
George Tetz, MD, Ph.D., CEO of CLS Therapeutics, presented a poster on their anticancer gene therapy platform at the Targeting Tumor Heterogeneity Conference organized by the New York Academy of Sciences.